{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:20:12Z","timestamp":1792200012965,"version":"4.4.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014091","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>The initiation of heart failure (HF) therapies at the time of detection of an elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) level in community-based patients with suspected HF may reduce the risk of early adverse outcomes. The aim of this analysis was to estimate the potential benefit of the early initiation of a sodium-glucose cotransporter 2 inhibitor (SGLT2i) and\/or mineralocorticoid receptor antagonist (MRA) in patients with suspected HF and a pre-existing non-HF-related indication for treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort study was performed from 1 January 2015 to 31 March 2023 using linked primary and secondary care data from the Clinical Practice Research Datalink (CPRD). Patients without a history of HF and who were not prescribed an SGLT2i or MRA were followed up for 12\u2005months following a community-measured NT-proBNP \u2265 400\u2005pg\/mL. The primary outcome was a composite of a HF hospitalization as the first recorded HF diagnostic event or death from any cause in patients without a documented HF diagnosis during follow-up and who did not undergo echocardiography. The effect of the initiation of treatment with an SGLT2i, MRA, or both (effective treatments for HF regardless of ejection fraction) was modelled at the time of NT-proBNP measurement in patients with a pre-existing non-HF-related indication for these drugs (Type 2 diabetes, chronic kidney disease, or resistant hypertension) using treatment effect estimates from meta-analyses of randomized placebo-controlled trials in patients with established HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>An NT-proBNP \u2265 400\u2005pg\/mL was recorded in 74 945, 24 082 (32%) of whom had a HF diagnosis recorded within 12\u2005months, 15 398 (64%) as an outpatient and 8684 (36%) during a HF hospitalization. If both an SGLT2i and MRA were commenced at the measurement of an elevated NT-proBNP in those with a pre-existing non-HF-related indication, we estimated that for every 1000 patients treated, 84 would avoid either a HF hospitalization or death at 12\u2005months, equating to a number needed to treat of 12 (95% confidence interval 11\u201314).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In community-based patients with suspected HF and elevated NT-proBNP, the early initiation of an SGLT2i and an MRA in patients with a pre-existing non-HF-related indication for treatment may reduce the risk of early adverse outcomes whilst awaiting diagnostic echocardiography. These findings suggest a simple clinical strategy with potentially large public health benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf675","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T11:23:46Z","timestamp":1755516226000},"page":"927-938","source":"Crossref","is-referenced-by-count":15,"title":["Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5446-9969","authenticated-orcid":false,"given":"Kieran F","family":"Docherty","sequence":"first","affiliation":[{"name":"School of Cardiovascular & Metabolic Health, BHF Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6549-0579","authenticated-orcid":false,"given":"Benjamin","family":"Heywood","sequence":"additional","affiliation":[{"name":"Human Data Sciences , Cardiff ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3044-197X","authenticated-orcid":false,"given":"Antoni","family":"Bayes-Genis","sequence":"additional","affiliation":[{"name":"CIBERCV, University Hospital Germans Trias i Pujol , Badalona, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0050-2129","authenticated-orcid":false,"given":"Ross T","family":"Campbell","sequence":"additional","affiliation":[{"name":"School of Cardiovascular & Metabolic Health, BHF Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8903-4906","authenticated-orcid":false,"given":"Alasdair D","family":"Henderson","sequence":"additional","affiliation":[{"name":"School of Cardiovascular & Metabolic Health, BHF Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-5317","authenticated-orcid":false,"given":"Pardeep S","family":"Jhund","sequence":"additional","affiliation":[{"name":"School of Cardiovascular & Metabolic Health, BHF Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6635-1466","authenticated-orcid":false,"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen University Hospital , Hellerup ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-2466","authenticated-orcid":false,"given":"Morten","family":"Schou","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen ,","place":["Denmark"]},{"name":"Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte Hospital , Hellerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-9597","authenticated-orcid":false,"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-1953","authenticated-orcid":false,"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7649-4332","authenticated-orcid":false,"given":"Jil Billy","family":"Mamza","sequence":"additional","affiliation":[{"name":"Medical and Scientific Affairs, BioPharmaceuticals Medical, AstraZeneca UK Limited , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Ll","family":"Morgan","sequence":"additional","affiliation":[{"name":"Human Data Sciences , Cardiff ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Mullin","sequence":"additional","affiliation":[{"name":"Cardiovascular, Renal and Metabolism Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical and Scientific Affairs, BioPharmaceuticals Medical, AstraZeneca UK Limited , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4517-272X","authenticated-orcid":false,"given":"Mark C","family":"Petrie","sequence":"additional","affiliation":[{"name":"School of Cardiovascular & Metabolic Health, BHF Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"School of Cardiovascular & Metabolic Health, BHF Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"2026022311024596500_ehaf675-B1","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/heartjnl-2017-312183","article-title":"Routes to diagnosis of heart failure: observational study using linked data in England","volume":"104","author":"Bottle","year":"2018","journal-title":"Heart"},{"key":"2026022311024596500_ehaf675-B2","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1136\/heartjnl-2018-313971","article-title":"Adherence to guidelines in management of symptoms suggestive of heart failure in primary care","volume":"105","author":"Hayhoe","year":"2019","journal-title":"Heart"},{"key":"2026022311024596500_ehaf675-B3","doi-asserted-by":"publisher","first-page":"e1002805","DOI":"10.1371\/journal.pmed.1002805","article-title":"Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: a cohort study of 93,000 UK patients","volume":"16","author":"Conrad","year":"2019","journal-title":"PLoS Med"},{"key":"2026022311024596500_ehaf675-B4","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/eurheartj\/ehaf034","article-title":"Suspected de novo heart failure in outpatient care: the REVOLUTION HF study","volume":"46","author":"Anderson","year":"2025","journal-title":"Eur Heart J"},{"key":"2026022311024596500_ehaf675-B5","doi-asserted-by":"publisher","first-page":"e021856","DOI":"10.1136\/bmjopen-2018-021856","article-title":"Does specialist review for patients with suspected heart failure predict better outcomes? An observational study on the utility of compliance with NICE guidelines","volume":"8","author":"Morton","year":"2018","journal-title":"BMJ Open"},{"key":"2026022311024596500_ehaf675-B6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"2026022311024596500_ehaf675-B7","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med"},{"key":"2026022311024596500_ehaf675-B8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"key":"2026022311024596500_ehaf675-B9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamacardio.2020.7585","article-title":"Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction","volume":"6","author":"Berg","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026022311024596500_ehaf675-B10","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"2026022311024596500_ehaf675-B11","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1001\/jamacardio.2022.3750","article-title":"Time to clinical benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial","volume":"7","author":"Vaduganathan","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026022311024596500_ehaf675-B12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ejhf.2420","article-title":"Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial","volume":"24","author":"Butler","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026022311024596500_ehaf675-B13","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/ejhf.2952","article-title":"Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from the EMPHASIS-HF trial","volume":"25","author":"Monzo","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026022311024596500_ehaf675-B14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jacc.2024.09.018","article-title":"Time to significant benefit of finerenone in patients with heart failure","volume":"85","author":"Vaduganathan","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026022311024596500_ehaf675-B15","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026022311024596500_ehaf675-B16","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026022311024596500_ehaf675-B17","doi-asserted-by":"publisher","first-page":":1278\u2013","DOI":"10.1016\/j.cardfail.2025.02.014","article-title":"JCS\/JHFS 2025 Guideline on diagnosis and treatment of heart failure","volume":"89","author":"Kitai","year":"2025","journal-title":"J Card Fail"},{"key":"2026022311024596500_ehaf675-B18","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.hlc.2025.05.094","article-title":"iCARDIO alliance global implementation guidelines on heart failure 2025","volume":"34","author":"Chopra","year":"2025","journal-title":"Heart Lung Circ"},{"key":"2026022311024596500_ehaf675-B19","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026022311024596500_ehaf675-B20","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension: developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO)","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026022311024596500_ehaf675-B21","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.2337\/dc22-0614","article-title":"Prescription patterns of cardiovascular- and kidney-protective therapies among patients with type 2 diabetes and chronic kidney disease","volume":"45","author":"Lamprea-Montealegre","year":"2022","journal-title":"Diabetes Care"},{"key":"2026022311024596500_ehaf675-B22","author":"National Institute for Health and Care Excellence"},{"key":"2026022311024596500_ehaf675-B23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1067\/mhj.2001.111262","article-title":"Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo","volume":"141","author":"Fisher","year":"2001","journal-title":"Am Heart J"},{"key":"2026022311024596500_ehaf675-B24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"2026022311024596500_ehaf675-B25","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/ejhf.3036","article-title":"Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: a clinical consensus statement from the Heart Failure Association of the ESC","volume":"25","author":"Bayes-Genis","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026022311024596500_ehaf675-B26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026022311024596500_ehaf675-B27","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026022311024596500_ehaf675-B28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehaf675\/64147366\/ehaf675.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehaf675\/64147366\/ehaf675.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehaf675\/64147366\/ehaf675.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:02:59Z","timestamp":1771862579000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/8\/927\/8242485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,29]]},"published-print":{"date-parts":[[2026,2,23]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf675","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,21]]},"published":{"date-parts":[[2025,8,29]]}}}